Every October, we unite to bring attention to breast cancer, the most common cancer among women worldwide.
At EDM, we are committed to supporting women's health through education, advocacy, and high-quality medical supplies. Together, we can make a difference in the fight against breast cancer.
Partnering for Breast Cancer Awareness and Early Detection
Reducing the breast cancer mortality rate begins with expanding access to life-saving preventative care. We are proud to partner with GE HealthCare and the Île-de-France Cancer Screening Center this October.
Supporting life-saving preventative care
The Mammo Solidaire screening truck will be accessible throughout the Paris region during the month of October, giving free-of-charge mammograms to all women between the ages of 50-74 who have not been screened in over two years. House calls offer breast cancer screening that is even more convenient and accessible to women in a high-risk group—a message the campaign hopes to convey with early detection.
EDM Imaging, our parent company, adds to that impact with its mammography films and consumables that contribute to the very positive effect this initiative has. Our products ensure high-quality images, so fundamentally important for good and accurate screenings, enabling the healthcare provider to provide the best care possible for those patients.
Join us in promoting breast cancer awareness, early detection, and improved patient outcomes.
Advancing Women's Health Together
We remain committed to advancing women's health through high-quality products designed with care. As we honor Breast Cancer Awareness Month, we continue to support our clinical partners at Ob/Gyn practices across the country with the essential supplies they need to provide the best care for their patients.
View Women's Health Collection
Breast Cancer by the Numbers
1 in 8 women in the U.S. will be diagnosed with breast cancer in her lifetime
Early detection, through regular screenings like mammograms, can significantly improve outcomes. This disease not only impacts those diagnosed but also families, caregivers, and communities. Encouraging women to take proactive steps in their health is vital, whether through regular check-ups, genetic testing, or understanding their risk factors.
Current 5-year relative survival rate of 91% (all SEER stages combined)
The overall 5-year relative survival rate for breast cancer is approximately 91%, which combines all SEER stages. However, survival rates can differ based on the cancer subtype. For example, patients with the HR+/HER2- subtype experience the highest 5-year survival rate of 95.1%, whereas the HR-/HER2- subtype, which is more aggressive, has a lower 5-year survival rate of 78%.
About 310,720 new cases of invasive breast cancer will be diagnosed in 2024
In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in women in the U.S., making it the most common cancer among American women, second only to skin cancer. Breast cancer incidence rates have been rising slightly, by about 1% annually over the last decade. This increase is partly attributed to factors like changes in reproductive behaviors, such as declining birth rates, and higher rates of obesity.
While overall mortality rates from breast cancer have declined by 44% since 1989 due to advances in early detection and treatment, disparities remain concerning. For example, Black women are 37% more likely to die from breast cancer than white women, despite a lower overall incidence rate. Additionally, breast cancer is rising among younger women, particularly those under 50, where incidence rates have increased annually by 1.4%, especially among Asian American/Pacific Islander women.
Implications for Clinical Practice
These trends underscore the importance of vigilant screening, particularly in high-risk populations. Clinicians should consider these disparities when developing screening protocols and ensure that all women, especially those from underserved populations, have access to early detection services.
As clinicians, it's crucial to stay informed on these statistics to better guide patient care and advocate for equitable access to screenings and treatments across diverse communities.
